Login to Your Account



Immatics’ Series D Adds $46M for Phase III Renal Cancer Trial

By Nuala Moran
Staff Writer

Wednesday, October 16, 2013
LONDON – Immatics Biotechnologies GmbH closed a €34 million (US$46.1 million) Series D financing, enabling it to complete Phase III development of its lead cancer vaccine IMA901 in renal cancer and complete all preparations for filing with the FDA and the European Medicines Agency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription